Bristol Myers Stock’s Dividends Couldn’t Close The Gap

BMYYTD+18.8%SPYYTD+8.2%XLVYTD+21.1%
Analyze BMY →

Today’s big story: Anthropic IPO: Priced For 2031, Or 2036?

Bristol Myers Squibb (BMY) sells medicines such as Eliquis and Opdivo. It also pays its shareholders a dividend that came to a 4.1% yield at the November 17, 2026 close. Over the past five years, the stock has lagged far behind the S&P 500. Take a guess: once every dividend is counted, how did a five-year holder do against the market?

Image from Pixabay

How Far Has Bristol Myers Stock Trailed The Market?

Investors watching only the share price saw almost nothing to show for five years. Bristol Myers stock rose just 3.2% over the past five years on price alone, trailing a 56.7% advance for the S&P 500. That left the shares 53.5 percentage points behind the broader market.

How Much Did Bristol Myers’s Dividends Add?

Most of a shareholder’s five-year return came from payouts rather than the share price. A five-year holder of Bristol Myers made 26.9% when factoring in reinvested dividends. Those cash distributions, combined with the gains on the shares they bought, accounted for 23.7 percentage points of the overall return.

Did Dividends Close The Gap For Bristol Myers Holders?

A fair comparison also factors in the market’s dividends, placing both sets of returns side by side in the table below.

Return from Nov 9, 2021 to Nov 17, 2026 On price alone With dividends reinvested
The stock +3.2% +26.9%
S&P 500 +56.7% +67.6%

Before taxes and costs. The S&P 500 is measured through the SPDR S&P 500 ETF.

With dividends, the S&P 500 returned 67.6% over the same five years. Even after counting every payout, Bristol Myers holders finished 40.6 percentage points behind the market.

Bristol Myers’s dividends added more than twice the 10.8 points that S&P 500 dividends added. But the index still kept most of its lead. Bristol Myers’s dividends closed only about a quarter of the gap left by its share price.

What It Means To Own Bristol Myers For Income

The past year looked better for an income holder. Dividends added 5.9 percentage points to Bristol Myers’s return, against 1.2 for the S&P 500. Over that year, Bristol Myers stock rose 31.5% on price alone, against 9.0% for the S&P 500. With dividends, it returned 37.4%, against 10.2%. Over five years, though, that extra cash came with a share price that left holders far behind the market.

Bristol Myers pays that dividend out of what its medicines earn. Eliquis alone brought in 30.0% of its revenue in fiscal 2025. On its October 29, 2026 call, management said the company continues to return cash to shareholders through its commitment to the dividend. On the same call, management said it anticipates a $1.5 billion to $2 billion step down in Eliquis sales in 2027.

For an income holder, the yield on its own is not the number to watch. The number to watch is Bristol Myers’s return with dividends against the S&P 500’s return with dividends.

Bristol Myers paid its holders more cash than the market did and still left them behind, because its share price did so little. Income does the most for a holder when the share price also keeps pace with the market.

More Income. Smaller Drops.

Is your portfolio paying you enough? The Trefis Income Solution holds 50 dividend stocks yielding about 3x the S&P 500, each with at least 10 straight years of dividends. It lost less than the S&P 500 in all 9 big selloffs since 2018. Why not choose a better approach?

See The Income Solution

Spot an error or want more like this? Tell us in 10 seconds.